MD4215C1 - Inhibitor of human myeloid leukemia based on N-(4-(5-(pyridin-2-yl)-4,5-dihydro-1H-pyrazol-3-yl)phenyl)-2-(pyridin-2-ylmethylen)-hydrazinecarbothioamide - Google Patents

Inhibitor of human myeloid leukemia based on N-(4-(5-(pyridin-2-yl)-4,5-dihydro-1H-pyrazol-3-yl)phenyl)-2-(pyridin-2-ylmethylen)-hydrazinecarbothioamide

Info

Publication number
MD4215C1
MD4215C1 MDA20120059A MD20120059A MD4215C1 MD 4215 C1 MD4215 C1 MD 4215C1 MD A20120059 A MDA20120059 A MD A20120059A MD 20120059 A MD20120059 A MD 20120059A MD 4215 C1 MD4215 C1 MD 4215C1
Authority
MD
Moldova
Prior art keywords
pyridin
myeloid leukemia
human myeloid
ylmethylen
hydrazinecarbothioamide
Prior art date
Application number
MDA20120059A
Other languages
Romanian (ro)
Russian (ru)
Other versions
MD4215B1 (en
Inventor
Никанор БАРБА
Аурелиан ГУЛЯ
Анна ПОПУШОЙ
Анжела ЖАЛБЭ
Original Assignee
Государственный Университет Молд0
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Государственный Университет Молд0 filed Critical Государственный Университет Молд0
Priority to MDA20120059A priority Critical patent/MD4215C1/en
Publication of MD4215B1 publication Critical patent/MD4215B1/en
Publication of MD4215C1 publication Critical patent/MD4215C1/en

Links

Landscapes

  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to organic chemistry, namely to the synthesis of biologically active compounds from the group of hydrazinecarbothioamides with heterocyclic nuclei which can be used for prevention and treatment of human myeloid leukemia.Summary of the invention consists in that as an inhibitor of human myeloid leukemia (HL-60 cells) is proposed a new compound N-(4-(5-(pyridin-2-yl)-4,5-dihydro-1H-pyrazol-3-yl)phenyl)-2-(pyridin-2-ylmethylen)-hydrazinecarbothioamide with the formula:The claimed compound possesses inhibitory properties of human myeloid leukemia.
MDA20120059A 2012-07-09 2012-07-09 Inhibitor of human myeloid leukemia based on N-(4-(5-(pyridin-2-yl)-4,5-dihydro-1H-pyrazol-3-yl)phenyl)-2-(pyridin-2-ylmethylen)-hydrazinecarbothioamide MD4215C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MDA20120059A MD4215C1 (en) 2012-07-09 2012-07-09 Inhibitor of human myeloid leukemia based on N-(4-(5-(pyridin-2-yl)-4,5-dihydro-1H-pyrazol-3-yl)phenyl)-2-(pyridin-2-ylmethylen)-hydrazinecarbothioamide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MDA20120059A MD4215C1 (en) 2012-07-09 2012-07-09 Inhibitor of human myeloid leukemia based on N-(4-(5-(pyridin-2-yl)-4,5-dihydro-1H-pyrazol-3-yl)phenyl)-2-(pyridin-2-ylmethylen)-hydrazinecarbothioamide

Publications (2)

Publication Number Publication Date
MD4215B1 MD4215B1 (en) 2013-04-30
MD4215C1 true MD4215C1 (en) 2013-11-30

Family

ID=48227600

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20120059A MD4215C1 (en) 2012-07-09 2012-07-09 Inhibitor of human myeloid leukemia based on N-(4-(5-(pyridin-2-yl)-4,5-dihydro-1H-pyrazol-3-yl)phenyl)-2-(pyridin-2-ylmethylen)-hydrazinecarbothioamide

Country Status (1)

Country Link
MD (1) MD4215C1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD4393C1 (en) * 2015-09-04 2016-08-31 Государственный Университет Молд0 Inhibitor of human myeloid leukemia HL-60 cells based on nitrato-[N′-(1-pyridine-2-ylmethylidene)-morpholine-4-carbothiohydrazido(1-)]copper
MD4407C1 (en) * 2015-04-29 2016-10-31 Государственный Университет Молд0 Inhibitor of human myeloid leukemia HL-60 cells based on bis[N-(prop-2-en-1-yl)-2-(pyridine-2-ylmethylidene)hydrazinecarbothioamide]nickel(II) chloride hydrate
MD4434C1 (en) * 2015-10-09 2017-04-30 Государственный Университет Молд0 Use of N'-[1-(2-pyridyl)ethylidene]morpholin-4-carbothiohydrazide as a human myeloid leukemia HL-60 cell proliferation inhibitor

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD4349C1 (en) * 2014-06-23 2015-12-31 Государственный Университет Молд0 N-(3-methoxyphenyl)-2-(pyridine-2-ylmethylene)-hydrazinecarbothioamide compound - inhibitor of human melanoma MeW-164 cell proliferation
MD4520C1 (en) * 2016-12-16 2018-05-31 Государственный Университет Молд0 N-(4-butoxyphenyl)-2-(pyridin-2-ylmethylidene)hydrazinecarbothioamide as T-47D breast cancer cells growth inhibitor

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565491A (en) * 1994-01-31 1996-10-15 Bristol-Myers Squibb Company Use of phosphotyrosine phospatase inhibitors for controlling cellular proliferation
MD2786G2 (en) * 2004-05-11 2006-02-28 Государственный Университет Молд0 Inhibitors of human myeloid leukemia on base of heteronuclear coordinative compounds of cobalt(III) and bismuth(III)
MD2851G2 (en) * 2004-08-12 2006-04-30 Государственный Университет Молд0 Inhibitor of human myeloid leukemia on base of asymmetric cobalt trichloroacetate dimer
MD3098G2 (en) * 2006-01-03 2007-02-28 Государственный Университет Молд0 Dihydrate of di( -Ophenoxy)-di[N-(2-oxy-1-benzal)-N1- -oxyfuralhydrazine(2-)copper] with properties of inhibitor of the human myeloid leukemia
MD3655G2 (en) * 2007-09-03 2009-02-28 Государственный Университет Молд0 Inhibitor of human myeloid leukemia on base of bis(2-hydroxy-8-phenyl-tricyclo/7.3.1.0.2,7/-tridecane-13-on-thiosemicarbazonato)copper
MD3890G2 (en) * 2008-09-08 2009-12-31 Государственный Университет Молд0 Inhibitors of human myeloid leukemia on base of coordinative compounds of copper(II) with salicylidene thiocarbazides
US20100197711A1 (en) * 2007-09-27 2010-08-05 Keith Geoffrey Watson Benzothiazole compounds
MD4126B1 (en) * 2010-11-15 2011-09-30 Univ De Stat Din Moldova N,N'-[4,4'-(perfluoro-1,4-phenylenedioxy)-bis(4,1-phenylene)]-bis[2-(pyridine-2-ilmethylene)hydrazinecarbothioamide] and use thereof as prostate cancer LNCaP cell proliferation inhibitor

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565491A (en) * 1994-01-31 1996-10-15 Bristol-Myers Squibb Company Use of phosphotyrosine phospatase inhibitors for controlling cellular proliferation
MD2786G2 (en) * 2004-05-11 2006-02-28 Государственный Университет Молд0 Inhibitors of human myeloid leukemia on base of heteronuclear coordinative compounds of cobalt(III) and bismuth(III)
MD2851G2 (en) * 2004-08-12 2006-04-30 Государственный Университет Молд0 Inhibitor of human myeloid leukemia on base of asymmetric cobalt trichloroacetate dimer
MD3098G2 (en) * 2006-01-03 2007-02-28 Государственный Университет Молд0 Dihydrate of di( -Ophenoxy)-di[N-(2-oxy-1-benzal)-N1- -oxyfuralhydrazine(2-)copper] with properties of inhibitor of the human myeloid leukemia
MD3655G2 (en) * 2007-09-03 2009-02-28 Государственный Университет Молд0 Inhibitor of human myeloid leukemia on base of bis(2-hydroxy-8-phenyl-tricyclo/7.3.1.0.2,7/-tridecane-13-on-thiosemicarbazonato)copper
US20100197711A1 (en) * 2007-09-27 2010-08-05 Keith Geoffrey Watson Benzothiazole compounds
MD3890G2 (en) * 2008-09-08 2009-12-31 Государственный Университет Молд0 Inhibitors of human myeloid leukemia on base of coordinative compounds of copper(II) with salicylidene thiocarbazides
MD4126B1 (en) * 2010-11-15 2011-09-30 Univ De Stat Din Moldova N,N'-[4,4'-(perfluoro-1,4-phenylenedioxy)-bis(4,1-phenylene)]-bis[2-(pyridine-2-ilmethylene)hydrazinecarbothioamide] and use thereof as prostate cancer LNCaP cell proliferation inhibitor

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Mohamed Ashraf Ali, Mohammad Shaharyar*, Anees Ahamed Siddiqui, Synthesis, structural activity relationship and anti-tubercular activity of novel pyrazoline derivatives Faculty of Pharmacy, Jamia Hamdard University, Department of Pharmaceutical Chemistry, Hamdard Nagar, New Delhi 110062, India, Received 22 February 2006; received in revised form 22 July 2006; accepted 11 August 2006, Available online 26 September 2006, Eropean Journal of Medicinal Chemistry, 42 (2007), 268-276 *
Mukherjee S. Împăratul tuturor bolilor: o biografie a cancerului. Editura ALL, 2011, pag 50, 95,136, 424 *
Ozan Nuhoglu, Zuhal Ozdemir, Unsal Calis, Bulent Gumusel and Abdullah Altan Bilgin. Synthesis of and Pharmacological studies on The Antidepressant and Anticonvulsant Activities of some 1,3,5-Trisubstituted Pyrazolines // Arzneim- Forsch.Drug Res, 55, Nr. 8, 2005 p. 431-436 *
Res. Cancer. Epidemiol. S. R. Heckbert. "Glutathione transferase and epoxide hydrolase activities in patients with cancer and controls", 1989, Lyon, p. 515-516. *
Машковский М. Д. Лекарственные средства. Москва, Новая волна, 2008, с. 1206 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD4407C1 (en) * 2015-04-29 2016-10-31 Государственный Университет Молд0 Inhibitor of human myeloid leukemia HL-60 cells based on bis[N-(prop-2-en-1-yl)-2-(pyridine-2-ylmethylidene)hydrazinecarbothioamide]nickel(II) chloride hydrate
MD4393C1 (en) * 2015-09-04 2016-08-31 Государственный Университет Молд0 Inhibitor of human myeloid leukemia HL-60 cells based on nitrato-[N′-(1-pyridine-2-ylmethylidene)-morpholine-4-carbothiohydrazido(1-)]copper
MD4434C1 (en) * 2015-10-09 2017-04-30 Государственный Университет Молд0 Use of N'-[1-(2-pyridyl)ethylidene]morpholin-4-carbothiohydrazide as a human myeloid leukemia HL-60 cell proliferation inhibitor

Also Published As

Publication number Publication date
MD4215B1 (en) 2013-04-30

Similar Documents

Publication Publication Date Title
MX338489B (en) Hydantoin derivatives useful as kv3 inhibitors.
EA201590748A1 (en) ANTI-VIRUS CONNECTIONS AGAINST RSV
UA111382C2 (en) Protein kinase inhibitors
MX2014002683A (en) Benzonitrile derivatives as kinase inhibitors.
MY192521A (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
WO2017087808A8 (en) Heterocyclic compounds that inhibit the kinase activity of mnk useful for treating various cancers
MX371353B (en) Aromatic heterocyclic compounds as antiinflammatory compounds.
JO3025B1 (en) Oxazole substituted indazoles as pi3 - kinase inhibitors
SG10201806965XA (en) 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer
EA201590661A1 (en) AZACHINASOLINE INHIBITORS OF ATYPICAL PROTEINKINASE C
GEP20146197B (en) New compounds
UA104731C2 (en) P38 map kinase inhibitors
MX2013007702A (en) Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors.
MX336726B (en) Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors.
MX356813B (en) Hydantoin derivatives useful as kv3 inhibitors.
PH12015502611A1 (en) Heterocyclic compounds as hedgehog signaling pathway inhibitors
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
MX2012007582A (en) 4-phenoxy-nicotinamide or 4-phenoxy-pyrimidine-5-carboxamide compounds.
MD4215C1 (en) Inhibitor of human myeloid leukemia based on N-(4-(5-(pyridin-2-yl)-4,5-dihydro-1H-pyrazol-3-yl)phenyl)-2-(pyridin-2-ylmethylen)-hydrazinecarbothioamide
MX2016007810A (en) N1-(3,3,3-trifluoro-2-hydroxo-2-methylpropionyl)-piperidine derivatives as inhibitors of pyruvate dehydrogenase kinase.
PH12016500735A1 (en) Substituted pyrimidine compounds and their use as syk inhibitors
TN2012000034A1 (en) Methylpyrrolopyrimidinecarboxamides
EA201792558A1 (en) ANTIGROADING 4- (4- (4 - (((3R, 5R) -5 - ((1H-1,2,4-TRIAZOL-1-IL) METHYL) -5- (2,4-DIFTORFENIL) TETRAHYDROFURAN-3 -IL) METHOXY) -3-METHYLPHENYL) PIPERAZIN-1-IL) -N- (2-HYDROXYCYCLOGEXYL) BENZMIDE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT
MD20110040A1 (en) Inhibitors of human myeloid leukemia based on 2-[2-(pyridine-2-ilmethylidene)hydrazine]-1,3-benzothiazole and 2-[2-(1-pyridine-2-ilethylidene)hydrazine]-1,3-benzothiazole dihydrate
IN2014KN00847A (en)

Legal Events

Date Code Title Description
FG4A Patent for invention issued
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MM4A Patent for invention definitely lapsed due to non-payment of fees